The Outcomes of Dapagliflozin Use in Real-Life Clinical Settings in Endocrinology Clinics of Islamabad, Pakistan

Introduction Dapagliflozin is a member of a novel class of drugs (sodium-glucose cotransporter-2 inhibitors) used to treat type 2 diabetes mellitus and licensed in Pakistan in 2017. This retrospective observational study evaluated the effects of dapagliflozin on glycated hemoglobin (HbA1c) concentra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamin, Matiullah, Ishtiaq, Osama, Raashid, Kashif, Wahab, Muhammad Umar, Khan, Sajjad Ali, Raja, Umar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294883/
https://www.ncbi.nlm.nih.gov/pubmed/32550088
http://dx.doi.org/10.7759/cureus.8565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294883/
https://www.ncbi.nlm.nih.gov/pubmed/32550088
http://dx.doi.org/10.7759/cureus.8565

Ejemplares similares